FOMX - フォ―ミックス・ファ―マシュ―ティカルズ (Foamix Pharmaceuticals Ltd.) フォ―ミックス・ファ―マシュ―ティカルズ

 FOMXのチャート


 FOMXの企業情報

symbol FOMx
会社名 Foamix Pharmaceuticals Ltd. (フォ―ミックス・ファ―マシュ―ティカルズ)
分野(sector) Consumer Durables   耐久消費財
産業(industry) Specialty Chemicals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations using its technology which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne rosacea and other skin conditions. Its product candidates include FMX101 FMX102 FMX103 and FDX104. Its lead product candidate FMX101 is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101 FMX102 FMX103 and FDX104.   フォ―ミックス・ファ―マシュ―ティカルズは、イスラエルの特殊医薬品会社。にきび、膿痂疹および他の皮膚疾患の治療用にミノサイクリンフォ―ムの開発、商品化を手掛ける。製品候補として、ミノサイクリンフォ―ム4%配合の中等度から重度のにきび用FMX101、ミノサイクリンフォ―ム1%配合の膿痂疹用FMX102の開発を行う。  Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
本社所在地 2 Holzman St. Weizmann Science Park Rehovot 7670402 ISR
代表者氏名
代表者役職名
電話番号 +972 8-931-6233
設立年月日 37622
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 75人
url www.foamix.co.il
nasdaq_url https://www.nasdaq.com/symbol/fomx
adr_tso
EBITDA EBITDA(百万ドル) -78.66200
終値(lastsale) 4.98
時価総額(marketcap) 203330033.52
時価総額 時価総額(百万ドル) 269.84650
売上高 売上高(百万ドル) 3.81400
企業価値(EV) 企業価値(EV)(百万ドル) 215.68150
当期純利益 当期純利益(百万ドル) -79.54900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Foamix Pharmaceuticals Ltd revenues increased 8% to $1.9M. Net loss increased 45% to $44.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 49% to $39.7M (expense) Selling general and administrative increase of 7% to $6.7M (expense) Financial Expense.

 FOMXのテクニカル分析


 FOMXのニュース

  ルイジアナ元検事総長によるFOAMIX INVESTOR ALERT:Kahn Swick&Foti、LLCは、Foamix Pharmaceuticals Ltd.-FOMXの販売提案における価格とプロセスの妥当性を調査します。 FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX  2019/11/23 01:04:00 Business Wire
「ニューオーリンズ-(BUSINESS WIRE)-(ビジネスワイヤ)-ルイジアナ州チャールズ・C・フォティ・ジュニア司法長官、カーン・スウィック・アンド・フォティ法律事務所(「KSF」)の法律事務所は、フォアミックス・ファーマシューティカルズの提案販売を調査しています。 Ltd.(NasdaqGS:FOMX)からMenlo Therapeutics Inc.(NasdaqGS:MNLO)。提案された取引の条件の下で、Foamixの株主は、所有するFoamixの各株式につき0.5924株のMenloと1つの条件付き株式のみを受け取ります。 KSFは、これが
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Foamix Pharmaceuticals Ltd. (NasdaqGS: FOMX ) to Menlo Therapeutics Inc. (NasdaqGS: MNLO). Under the terms of the proposed transaction, shareholders of Foamix will receive only 0.5924 shares of Menlo and one contingent stock right for each share of Foamix that they own. KSF is seeking to determine whether this
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.  2019/11/12 22:09:00 Benzinga Feeds
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX ) in connection with the proposed acquisition of the Company by Menlo Therapeutics, Inc. ("MNLO") (NASDAQ: MNLO ). Under the terms of the acquisition agreement, FOMX shareholders will receive 0.5924 shares of MNLO and a contingent stock right for each FOMX share they own. If you own FOMX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weisslawllp.com/foamix-pharmaceuticals-ltd/ Full story available on Benzinga.com
   FOAMIX ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of FOMX and Encourages Investors to Contact the Firm  2019/11/12 00:09:00 PR Newswire
NEW YORK, Nov. 11, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) breached their fiduciary duties or violated the federal securities…
   Menlo, Foamix stocks set for selloffs after all-stock merger deal  2019/11/11 13:00:00 Yahoo Finance
Shares of Menlo Therapeutics Ltd. was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. plunged 16%, after the company's announced a merger in which Foamix acquired Menlo in an all-stock deal. Under terms of the deal, each Foamix share will be exchanged for 0.5924 shares of Menlo common stock and a contingent stock right (CSR), which the companies said implies an 18% premium to Menlo's shareholders, based on the 10-day average volume-weighted price. Foamix shareholders will own 59% of the combined company. Menlo's lead product candidate, serlopitant, is being developed as a novel treatment for pruritus (itch), and Foamix's acne treatment Amzeeq has been approved by the Food and Drug Administration. If one of two of the phase 3 trials for serlopitant fails to meet its primary endpoint by May 31, 2020, Foamix shareholders will receive an additional 0.6815 of Menlo shares for each Foamix stock they own. If both phase 3 trials miss the primary endpoints, Foamix shareholders will receive an additional 1.2082 Menlo shares.
   Will Foamix (FOMX) Report Negative Q3 Earnings? What You Should Know  2019/10/30 14:33:30 Zacks Investment Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of…
   Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フォ―ミックス・ファ―マシュ―ティカルズ FOMX Foamix Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)